You are using an unsupported browser.
Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Pipeline

Development Programs – Solid Tumor

Drug

Indication

Phase 1

Phase 2

Phase 3


Tislelizumab

(anti-PD-1)
1L NSCLC, 1L Sq. NSCLC, 2/3L NSCLC

1L GC/GEJC

1L PD-L1 positive ESCC

2L ESCC

1L NPC, 1L ES-SCLC, 1L HCC

1L UBC, LA ESCC, Neo/adj NSCLC^

Neo/adj MSI-H or dMMR CRC

Resectable ESCC

NSCLC

Ociperlimab

(anti-TIGIT)
1L PD-L1 high NSCLC

1L NSCLC

2L+ PD-L1 positive ESCC

1L HCC

Solid Tumors

1L LS-SCLC

2/3L cervical cancer

LBL-007

(anti-LAG-3)
MSS-CRC

1L ESCC

Surzebiclimab

(anti-TIM-3)
Solid Tumors

Zanidatamab

(anti-HER2 BsAb)
HER2+ 2L BTC

1L HER2+ GEA

1L HER2+ mBC/GC

BGB-A445

(anti-OX40)
Melanoma, RCC, UC

Solid Tumors

BGB-15025 / 26808

(HPK1 inhibitor)
Solid Tumors

BGB-24714

(SMAC mimetic)
Solid Tumors

BGB-43395

(CDK4 inhibitor)
BC & Solid Tumors

BGB-3245

(BRAF inhibitor)
GI & Solid Tumors

BGB-B167

(CEA-4-1BB BsAB)
Solid Tumors

BGB-30813

(DGKζ inhibitor)
Solid Tumors

BGB-A3055

(anti-CCR8)
Solid Tumors

BGB-10188

(PI3Kδ inhibitor)
Solid Tumors

Pamiparib

(PARP 1/2 inhibitor)
2L MTx gBRCAm PSOC

Advanced ovarian cancer

Tarlatamab§

(DLL3 x CD3)
2L SCLC

Xaluritamig§

(STEAP1 x CD3)
mCRPC (initiation activities)

Lifirafenib

(RAF inhibitor)
Solid Tumors

Lenvatinib

(Tyrosine kinase inhibitor)
Solid Tumors

1L HCC

Surufatinib^^

(VEGFR, FGFR, CSF-1R inhibitor)
Solid Tumors

Fruquintinib^^

(VEGFR inhibitor)
GC/GEJC and CRC

00US3-TNBC/CRC/endometrial

DKN-01††

(anti-DKK1)
GC/GEJC

Sitravatinib‡‡

(multikinase inhibitor)
NSCLC post PD-(L)1 therapy

ESCC post PD-(L)1 therapy

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BsAb, bispecific antibody; BTC, biliary tract cancer; BRAF, v-raf murine sarcoma viral oncogene homolog B; CCR8, CC chemokine receptor 8; CD3, cluster of differentiation 3; CDK4, cyclin-dependent kinase 4; CEA-4-1BB, carcinoembryonic antigen-specific 4-1BB; CRC, colorectal cancer; CSF-1R, colony-stimulating factor-1 receptor; DGKζ, diacylglycerol kinase ζ; DKK1, dickkopf-1; DLL3, delta-like ligand 3; dMMR, deficient mismatch repair; ESCC, esophageal squamous cell carcinoma; ES-SCLC, extensive-stage small cell lung cancer; FGFR, fibroblast growth factor receptor; gBRCAm, germline BRCA mutation; GC, gastric cancer; GC-GEJC, gastric cancer-gastroesophageal junction carcinoma;GEA, gastroesophageal adenocarcinomas; GEJC, gastroesophageal junction carcinoma; GI, gastrointestinal; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; HPK1, hematopoietic progenitor kinase 1; 1L, first line; 2L, second line; LA, locally advanced; LAG-3, lymphocyte activation gene 3 protein; mBC, metastatic breast cancer; mCRPC, metastatic castration-resistant prostate cancer; MSI-H, microsatellite instability-high; MTx, maintenance treatment; NPC, nasopharyngeal carcinoma; NonSq, non-squamous; NSCLC, non-small cell lung cancer; OX40, a member of the tumor necrosis factor (TNF) receptor family, also know as CD134; PARP, poly(ADP-ribose) polymerase; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PI3Kδ, phosphoinositide 3-kinase delta; PSOC, platinum-sensitive ovarian cancer; RAF, rapidly accelerated fibrosarcoma; RCC, renal cell carcinoma; SCLC, small cell lung cancer; SMAC, second mitochondria-derived activator of caspase; STEAP1, Six-Transmembrane Epithelial Antigen of the Prostate 1; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer; UC, urothelial carcinoma; VEGFR, vascular endothelial growth factor receptors.

^Primary endpoint met.
Leads Biolabs collaboration, BeiGene has ex-China commercial rights.
Zymeworks/Jazz collaboration, BeiGene has APAC/ex Japan, AU, NZ commercial rights.
§Amgen collaboration, BeiGene has China commercial rights.
In collaboration with SpringWorks Therapeutics, Inc.
^^Clinical collaboration with Hutchison Medipharma International.
††In collaboration with Leap Therapeutics, Inc.
‡‡Partnership with Mirati Therapeutics, Inc.

Development Programs – Hematology

Drug

Indication

Phase 1

Phase 2

Phase 3


Zanubrutinib

(BTK inhibitor)
CLL/SLL

WM

R/R FL

R/R MZL

R/R MCL

R/R DLBCL

Previously treated B-cell malignancies

Sonrotoclax

(BCL2 inhibitor)
TN CLL*

R/R WM

R/R CLL

R/R MCL

R/R MM with t(11;14)**

Myeloid malignancies***

B-cell malignancies

BGB-16673

(BTK-targeted CDAC)
B-cell malignancies

BGB-21447

(BCL2 inhibitor)
B-cell malignancies

BGB-10188

(PI3Kδ inhibitor)
B-cell malignancies

AMG 176§

(MCL-1 inhibitor)
Hematologic malignancies

Tislelizumab

(anti-PD-1)
R/R cHL

Ociperlimab

(anti-TIGIT)
R/R DLBCL

Safety and efficacy have not been established for investigational products and/or uses.

CDAC, chimeric degradation activating compound; cHL, classical Hodgkin lymphoma; CLL/SLL, chronic lymphocytic leukemia/small lymphocytic lymphoma; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PI3Kδ, phosphoinositide 3-kinase delta; R/R, recurrent/refractory; TIGIT, T-cell immunoreceptor with Ig and ITIM domains.

* in combination with Zanubrutinib.
** +Dexamethasone +/– Carfilzomib.
*** +Azacitidine +/– Posaconazole.
§Amgen collaboration, BeiGene has China commercial rights.

Videos

Anti-OX40 Mechanism of Action

Anti-PD-1 Mechanism of Action

CDK4 Inhibitor Mechanism of Action

BTKI Mechanism of Action

Anti-TIGIT Mechanism of Action

PARPI Mechanism of Action